117 related articles for article (PubMed ID: 24269715)
1. Efficiency of the Therascreen® RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas.
Vallée A; Le Loupp AG; Denis MG
Clin Chim Acta; 2014 Feb; 429():8-11. PubMed ID: 24269715
[TBL] [Abstract][Full Text] [Related]
2. Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Hsiue EH; Lee JH; Lin CC; Yang JC
Expert Rev Mol Diagn; 2016 Dec; 16(12):1251-1257. PubMed ID: 27737606
[TBL] [Abstract][Full Text] [Related]
3. Highly Sensitive and Reliable Detection of EGFR Exon 19 Deletions by Droplet Digital Polymerase Chain Reaction.
Oskina N; Oscorbin I; Khrapov E; Boyarskikh U; Subbotin D; Demidova I; Imyanitov E; Filipenko M
Mol Diagn Ther; 2017 Oct; 21(5):555-562. PubMed ID: 28589341
[TBL] [Abstract][Full Text] [Related]
4. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer.
Kimura H; Ohira T; Uchida O; Matsubayashi J; Shimizu S; Nagao T; Ikeda N; Nishio K
Lung Cancer; 2014 Mar; 83(3):329-33. PubMed ID: 24439568
[TBL] [Abstract][Full Text] [Related]
5. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer.
Cushman-Vokoun AM; Crowley AM; Rapp SA; Greiner TC
Am J Clin Pathol; 2013 Jul; 140(1):7-19. PubMed ID: 23765529
[TBL] [Abstract][Full Text] [Related]
6. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
[TBL] [Abstract][Full Text] [Related]
7. therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer.
Syed YY
Mol Diagn Ther; 2016 Apr; 20(2):191-8. PubMed ID: 26891729
[TBL] [Abstract][Full Text] [Related]
8. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
[TBL] [Abstract][Full Text] [Related]
9. Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients.
Pasquale R; Fenizia F; Esposito Abate R; Sacco A; Esposito C; Forgione L; Rachiglio AM; Bevilacqua S; Montanino A; Franco R; Rocco G; Botti G; Denis MG; Morabito A; De Luca A; Normanno N
Pharmacogenomics; 2015; 16(10):1135-48. PubMed ID: 26249748
[TBL] [Abstract][Full Text] [Related]
10. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
[TBL] [Abstract][Full Text] [Related]
11. PCR-based testing for therapy-related EGFR mutations in patients with non-small cell lung cancer.
Dahse R; Berndt A; Kosmehl H
Anticancer Res; 2008; 28(4B):2265-70. PubMed ID: 18751405
[TBL] [Abstract][Full Text] [Related]
12. Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: applications of this method for the diagnosis of non-small-cell lung cancer.
Uhara M; Matsuda K; Taira C; Higuchi Y; Okumura N; Yamauchi K
Clin Chim Acta; 2009 Mar; 401(1-2):68-72. PubMed ID: 19063875
[TBL] [Abstract][Full Text] [Related]
13. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.
Zhao X; Han RB; Zhao J; Wang J; Yang F; Zhong W; Zhang L; Li LY; Wang MZ
Respiration; 2013; 85(2):119-25. PubMed ID: 22797485
[TBL] [Abstract][Full Text] [Related]
14. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Malapelle U; Bellevicine C; De Luca C; Salatiello M; De Stefano A; Rocco D; de Rosa N; Vitiello F; Russo S; Pepe F; Iaccarino A; Micheli P; Illiano A; Carlomagno C; Piantedosi FV; Troncone G
Cancer Cytopathol; 2013 Oct; 121(10):552-60. PubMed ID: 23780873
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
[TBL] [Abstract][Full Text] [Related]
16. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.
Pan Q; Pao W; Ladanyi M
J Mol Diagn; 2005 Aug; 7(3):396-403. PubMed ID: 16049312
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
[TBL] [Abstract][Full Text] [Related]
18. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.
Yung TK; Chan KC; Mok TS; Tong J; To KF; Lo YM
Clin Cancer Res; 2009 Mar; 15(6):2076-84. PubMed ID: 19276259
[TBL] [Abstract][Full Text] [Related]
19. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Chu H; Zhong C; Xue G; Liang X; Wang J; Liu Y; Zhao S; Zhou Q; Bi J
Oncol Rep; 2013 Nov; 30(5):2311-5. PubMed ID: 24002698
[TBL] [Abstract][Full Text] [Related]
20. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
